心舒宝片联合瑞舒伐他汀治疗高脂血症的临床研究

Clinical study on Xinshubao Tablets combined with rosuvastatin in treatment of hyperlipidemia

目的探讨心舒宝片联合瑞舒伐他汀钙片治疗高脂血症的临床疗效。方法选取2017年6月—2018年5月在涟水县人民医院治疗的高脂血症患者66例,根据用药的不同分为对照组(33例)和治疗组(33例)。对照组口服瑞舒伐他汀钙片,10mg/次,1次/d;治疗组在对照组基础上口服心舒宝片,1.0g/次,2次/d。两组均经过8周治疗。观察两组患者临床疗效,同时比较治疗前后两组患者血脂水平、炎性指标、血清摄食抑制因子-1(NSF-1)、瘦素(LEP)和脂联素(ADP)水平及氧化应激指标。结果治疗后,对照组临床有效率为81.82%,显著低于治疗组的96.97%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)、超敏C反应蛋白(hs-CRP)、白细胞介素-1β(IL-1β)、IL-6、嗜酸细胞阳离子蛋白(ECP)、NSF-1、LEP和丙二醛(MDA)水平均显著降低,高密度脂蛋白胆固醇(HDL-C)、ADP、超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GSH-Px)水平显著升高,同组比较差异具有统计学意义(P<0.05);且治疗后治疗组患者这些指标水平明显好于对照组,两组比较差异具有统计学意义(P<0.05)。结论心舒宝片联合瑞舒伐他汀钙片治疗高脂血症可有效降低患者血脂和血清炎性因子水平,改善机体氧化应激状态,具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Xinshubao Tablets combined with rosuvastatin in treatment of hyperlipidemia. Methods Patients(66 cases) with hyperlipidemia in Lianshui County People’s Hospital from June 2017 to May 2018 were divided into control(33 cases) and treatment(33 cases) groups bases on different treatments. Patients in the control group were po administered with Rosuvastatin Calcium Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Xinshubao Tablets on the basis of the control group, 1 g/time, twice daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the blood lipid levels, inflammatory markers, the serum NSF-1, LEP and ADP levels,and the oxidative stress indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 81.82%, which was significantly lower than 96.97% in the treatment group, and there were differences between two groups(P < 0.05). After treatment, the TC, TG, LDL-C, hs-CRP, IL-1β, IL-6, ECP, NSF-1, LEP and MDA levels in two groups were significantly decreased, but HDL-C, ADP, SOD and GSH-Px were significantly increased, and the difference was statistically significant in the same group(P < 0.05), and these indexes levels in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Xinshubao Tablets combined with rosuvastatin in treatment of hyperlipidemia can effectively reduce the level of blood lipids and serum inflammatory factors, improve the state of oxidative stress, which has a certain clinical application value.